Avidity Biosciences (RNA) Stock Forecast, Price Target & Predictions
RNA Stock Forecast
Avidity Biosciences stock forecast is as follows: an average price target of $50.00 (represents a 19.88% upside from RNA’s last price of $41.71) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
RNA Price Target
The average price target for Avidity Biosciences (RNA) is $50.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $50.00 to $50.00. This represents a potential 19.88% upside from RNA's last price of $41.71.
RNA Analyst Ratings
According to 7 Wall Street analysts, Avidity Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for RNA stock is 1 'Strong Buy' (14.29%), 6 'Buy' (85.71%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Avidity Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 12, 2024 | Yanan Zhu | Wells Fargo | $50.00 | $28.92 | 72.89% | 19.88% |
The latest Avidity Biosciences stock forecast, released on Jun 12, 2024 by Yanan Zhu from Wells Fargo, set a price target of $50.00, which represents a 72.89% increase from the stock price at the time of the forecast ($28.92), and a 19.88% increase from RNA last price ($41.71).
Avidity Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $50.00 |
| Last Closing Price | $41.71 | $41.71 | $41.71 |
| Upside/Downside | -100.00% | -100.00% | 19.88% |
In the current month, the average price target of Avidity Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Avidity Biosciences's last price of $41.71. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 28, 2024 | Barclays | - | Overweight | Initialise |
| Aug 12, 2024 | Needham | Buy | Buy | Hold |
| Aug 12, 2024 | Evercore Partners | Underperform | Underperform | Hold |
| Jun 25, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 13, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Jun 12, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Jun 12, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Jun 10, 2024 | Needham | Buy | Buy | Hold |
| May 03, 2024 | Needham | Buy | Buy | Hold |
| May 03, 2024 | Chardan Capital | Underperform | Underperform | Hold |
Avidity Biosciences's last stock rating was published by Barclays on Aug 28, 2024. The company Initialise its RNA rating from "null" to "Overweight".
Avidity Biosciences Financial Forecast
Avidity Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.82M | $2.32M | $2.23M | $2.77M | $2.48M | - | $1.79M | $1.85M | $2.16M | $2.61M | $2.70M | $2.14M | $1.75M | $1.54M |
| Avg Forecast | $4.33M | $4.02M | $3.73M | $3.46M | $4.03M | $4.03M | $4.03M | $4.03M | $2.45M | $4.32M | $2.63M | $2.57M | $12.21M | $2.21M | $2.14M | $2.04M | $2.16M | $2.13M | $2.11M | $1.90M | $2.17M | $2.13M | $1.94M | $1.00M | $838.75K | $575.00K | $700.00K |
| High Forecast | $4.33M | $4.02M | $3.73M | $3.46M | $4.03M | $4.03M | $4.03M | $4.03M | $2.45M | $4.32M | $2.63M | $2.57M | $23.86M | $2.21M | $2.14M | $2.04M | $2.16M | $2.13M | $2.11M | $1.90M | $2.17M | $2.13M | $1.94M | $1.00M | $838.75K | $575.00K | $700.00K |
| Low Forecast | $4.33M | $4.02M | $3.73M | $3.46M | $4.03M | $4.03M | $4.03M | $4.03M | $2.45M | $4.32M | $2.63M | $2.57M | $570.98K | $2.21M | $2.14M | $2.04M | $2.16M | $2.13M | $2.11M | $1.90M | $2.17M | $2.13M | $1.94M | $1.00M | $838.75K | $575.00K | $700.00K |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.27% | 1.08% | 1.09% | 1.28% | 1.17% | - | 0.94% | 0.85% | 1.02% | 1.35% | 2.70% | 2.55% | 3.04% | 2.20% |
Avidity Biosciences's average Quarter revenue forecast for Dec 23 based on 4 analysts is $12.21M, with a low forecast of $570.98K, and a high forecast of $23.86M. RNA's average Quarter revenue forecast represents a 333.33% increase compared to the company's last Quarter revenue of $2.82M (Sep 23).
Avidity Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-58.06M | $-52.63M | $-57.60M | $-53.23M | $-44.56M | - | $-34.15M | $-38.33M | $-29.10M | $-26.21M | $-23.74M | $-16.16M | $-11.34M | $-10.35M |
| Avg Forecast | $-4.33M | $-4.02M | $-3.73M | $-3.46M | $-4.03M | $-4.03M | $-4.03M | $-4.03M | $-2.45M | $-4.32M | $-2.63M | $-2.57M | $-12.21M | $-2.21M | $-2.14M | $-2.04M | $-2.16M | $-33.89M | $-2.11M | $-37.46M | $-2.17M | $-26.79M | $-28.59M | $-20.35M | $-838.75K | $-575.00K | $-29.11M |
| High Forecast | $-4.33M | $-4.02M | $-3.73M | $-3.46M | $-4.03M | $-4.03M | $-4.03M | $-4.03M | $-2.45M | $-4.32M | $-2.63M | $-2.57M | $-570.98K | $-2.21M | $-2.14M | $-2.04M | $-2.16M | $-27.11M | $-2.11M | $-29.97M | $-2.17M | $-21.43M | $-22.87M | $-16.28M | $-838.75K | $-575.00K | $-23.29M |
| Low Forecast | $-4.33M | $-4.02M | $-3.73M | $-3.46M | $-4.03M | $-4.03M | $-4.03M | $-4.03M | $-2.45M | $-4.32M | $-2.63M | $-2.57M | $-23.86M | $-2.21M | $-2.14M | $-2.04M | $-2.16M | $-40.67M | $-2.11M | $-44.95M | $-2.17M | $-32.15M | $-34.31M | $-24.41M | $-838.75K | $-575.00K | $-34.93M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.23% | 24.54% | 28.17% | 24.64% | 1.31% | - | 0.91% | 17.62% | 1.09% | 0.92% | 1.17% | 19.27% | 19.72% | 0.36% |
undefined analysts predict RNA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Avidity Biosciences's previous annual EBITDA (undefined) of $NaN.
Avidity Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-52.36M | $-47.02M | $-47.19M | $-47.72M | $-42.27M | - | $-34.01M | $-38.53M | $-29.27M | $-26.34M | $-23.83M | $-16.26M | $-11.41M | $-10.74M |
| Avg Forecast | $-117.10M | $-117.14M | $-109.49M | $-109.53M | $-84.47M | $-83.67M | $-78.86M | $-78.59M | $-83.37M | $-78.10M | $-80.86M | $-85.13M | $-70.50M | $-80.91M | $-84.80M | $-89.65M | $-95.08M | $-34.09M | $-67.09M | $-38.09M | $-53.05M | $-26.95M | $-28.75M | $-20.44M | $-26.05M | $-27.76M | $-29.69M |
| High Forecast | $-117.10M | $-117.14M | $-109.49M | $-109.53M | $-84.47M | $-83.67M | $-78.86M | $-78.59M | $-83.37M | $-54.67M | $-80.86M | $-85.13M | $9.14M | $-80.91M | $-84.80M | $-89.65M | $-95.08M | $-27.27M | $-67.09M | $-30.47M | $-53.05M | $-21.56M | $-23.00M | $-16.35M | $-26.05M | $-27.76M | $-23.75M |
| Low Forecast | $-117.10M | $-117.14M | $-109.49M | $-109.53M | $-84.47M | $-83.67M | $-78.86M | $-78.59M | $-83.37M | $-91.77M | $-80.86M | $-85.13M | $-114.89M | $-80.91M | $-84.80M | $-89.65M | $-95.08M | $-40.91M | $-67.09M | $-45.70M | $-53.05M | $-32.34M | $-34.50M | $-24.53M | $-26.05M | $-27.76M | $-35.63M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.65% | 0.55% | 0.53% | 0.50% | 1.24% | - | 0.89% | 0.73% | 1.09% | 0.92% | 1.17% | 0.62% | 0.41% | 0.36% |
Avidity Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RNA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Avidity Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $13.73M | $12.28M | $12.06M | $10.38M | $10.09M | - | $8.57M | $7.43M | $6.61M | $6.27M | $5.88M | $4.82M | $3.76M | $2.92M |
| Avg Forecast | $14.32M | $13.28M | $12.32M | $11.43M | $13.33M | $13.33M | $13.33M | $13.33M | $8.10M | $14.30M | $8.68M | $8.50M | $40.39M | $7.32M | $7.09M | $6.76M | $7.14M | $7.03M | $6.99M | $6.28M | $7.19M | $7.03M | $6.41M | $3.31M | $2.77M | $1.90M | $2.32M |
| High Forecast | $14.32M | $13.28M | $12.32M | $11.43M | $13.33M | $13.33M | $13.33M | $13.33M | $8.10M | $14.30M | $8.68M | $8.50M | $78.90M | $7.32M | $7.09M | $6.76M | $7.14M | $7.03M | $6.99M | $6.28M | $7.19M | $7.03M | $6.41M | $3.31M | $2.77M | $1.90M | $2.32M |
| Low Forecast | $14.32M | $13.28M | $12.32M | $11.43M | $13.33M | $13.33M | $13.33M | $13.33M | $8.10M | $14.30M | $8.68M | $8.50M | $1.89M | $7.32M | $7.09M | $6.76M | $7.14M | $7.03M | $6.99M | $6.28M | $7.19M | $7.03M | $6.41M | $3.31M | $2.77M | $1.90M | $2.32M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.88% | 1.73% | 1.78% | 1.45% | 1.44% | - | 1.36% | 1.03% | 0.94% | 0.98% | 1.78% | 1.74% | 1.98% | 1.26% |
Avidity Biosciences's average Quarter SG&A projection for Dec 23 is $40.39M, based on 4 Wall Street analysts, with a range of $1.89M to $78.90M. The forecast indicates a 194.16% rise compared to RNA last annual SG&A of $13.73M (Sep 23).
Avidity Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.71 | $-0.66 | $-0.67 | $-0.83 | $-0.80 | - | $-0.70 | $-1.63 | $-0.68 | $-0.70 | $-0.64 | $-0.43 | $-0.30 | $-1.25 |
| Avg Forecast | $-1.10 | $-1.10 | $-1.02 | $-1.02 | $-0.79 | $-0.78 | $-0.74 | $-0.73 | $-0.78 | $-0.73 | $-0.76 | $-0.80 | $-0.66 | $-0.76 | $-0.79 | $-0.84 | $-0.89 | $-0.93 | $-0.77 | $-0.80 | $-0.70 | $-0.68 | $-0.71 | $-0.56 | $-0.34 | $-0.36 | $-0.36 |
| High Forecast | $-1.10 | $-1.10 | $-1.02 | $-1.02 | $-0.79 | $-0.78 | $-0.74 | $-0.73 | $-0.78 | $-0.51 | $-0.76 | $-0.80 | $0.09 | $-0.76 | $-0.79 | $-0.84 | $-0.89 | $-0.93 | $-0.77 | $-0.80 | $-0.70 | $-0.68 | $-0.71 | $-0.56 | $-0.34 | $-0.36 | $-0.36 |
| Low Forecast | $-1.10 | $-1.10 | $-1.02 | $-1.02 | $-0.79 | $-0.78 | $-0.74 | $-0.73 | $-0.78 | $-0.86 | $-0.76 | $-0.80 | $-1.07 | $-0.76 | $-0.79 | $-0.84 | $-0.89 | $-0.93 | $-0.77 | $-0.80 | $-0.70 | $-0.68 | $-0.71 | $-0.56 | $-0.34 | $-0.36 | $-0.36 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 0.83% | 0.80% | 0.93% | 0.86% | - | 0.88% | 2.34% | 1.00% | 0.98% | 1.15% | 1.26% | 0.82% | 3.46% |
According to undefined Wall Street analysts, Avidity Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RNA previous annual EPS of $NaN (undefined).
Avidity Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| IGMS | IGM Biosciences | $12.30 | $25.00 | 103.25% | Buy |
| SWTX | SpringWorks Therapeutics | $37.42 | $67.33 | 79.93% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| RNA | Avidity Biosciences | $41.71 | $50.00 | 19.88% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
RNA Forecast FAQ
Is Avidity Biosciences a good buy?
Yes, according to 7 Wall Street analysts, Avidity Biosciences (RNA) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of RNA's total ratings.
What is RNA's price target?
Avidity Biosciences (RNA) average price target is $50 with a range of $50 to $50, implying a 19.88% from its last price of $41.71. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Avidity Biosciences stock go up soon?
According to Wall Street analysts' prediction for RNA stock, the company can go up by 19.88% (from the last price of $41.71 to the average price target of $50), up by 19.88% based on the highest stock price target, and up by 19.88% based on the lowest stock price target.
Can Avidity Biosciences stock reach $60?
RNA's average twelve months analyst stock price target of $50 does not support the claim that Avidity Biosciences can reach $60 in the near future.
What are Avidity Biosciences's analysts' financial forecasts?
Avidity Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $16.12M (high $16.12M, low $16.12M), average EBITDA is $-16.121M (high $-16.121M, low $-16.121M), average net income is $-326M (high $-326M, low $-326M), average SG&A $53.32M (high $53.32M, low $53.32M), and average EPS is $-3.045 (high $-3.045, low $-3.045). RNA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $15.53M (high $15.53M, low $15.53M), average EBITDA is $-15.53M (high $-15.53M, low $-15.53M), average net income is $-453M (high $-453M, low $-453M), average SG&A $51.36M (high $51.36M, low $51.36M), and average EPS is $-4.239 (high $-4.239, low $-4.239).
Did the RNA's actual financial results beat the analysts' financial forecasts?
Based on Avidity Biosciences's last annual report (Dec 2023), the company's revenue was $9.56M, which missed the average analysts forecast of $18.61M by -48.64%. Apple's EBITDA was $-236M, beating the average prediction of $-18.614M by 1165.69%. The company's net income was $-212M, missing the average estimation of $-326M by -34.87%. Apple's SG&A was $54.19M, missing the average forecast of $61.56M by -11.97%. Lastly, the company's EPS was $-2.91, missing the average prediction of $-3.048 by -4.51%. In terms of the last quarterly report (Sep 2023), Avidity Biosciences's revenue was $2.82M, beating the average analysts' forecast of $2.21M by 27.30%. The company's EBITDA was $-58.059M, beating the average prediction of $-2.214M by 2522.83%. Avidity Biosciences's net income was $-52.358M, missing the average estimation of $-80.909M by -35.29%. The company's SG&A was $13.73M, beating the average forecast of $7.32M by 87.53%. Lastly, the company's EPS was $-0.71, missing the average prediction of $-0.757 by -6.17%